Market News & Trends
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes & Weight Loss Market
PolyPid Ltd. recently unveiled its long-acting GLP-1 receptor agonists (glucagon-like peptide-1 RA) delivery platform that aims to subcutaneously release GLP-1 RA for approximately 60 days,…
Clearmind Expands Clinical Trial for Alcohol Use; New Site Activated & Additional Participant Enrolled
Clearmind Medicine Inc. recently announced the expansion of its Phase 1/2a clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder…
BiomX Announces Successful Initiation of Phase 2b Trial With First Patient Dosed in BX004 Program in Patients With Cystic Fibrosis
BiomX Inc. recently announced the successful initiation of patient dosing in the company’s Phase 2b trial with first patient dosed. The trial is evaluating BX004…
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment From Bain Capital, Kohlberg & Mubadala
PCI Pharma Services recently announced it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by…
Vivos Inc. Submitted the Investigational Device Exemption Application for Human Clinical Trials at Mayo Clinic
Vivos Inc., a pioneer in Precision Radionuclide Therapy (PRnT) solutions, recently announced the submission of its Investigational Device Exemption (IDE) application to the US FDA…
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
NEW YORK, MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication…
Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
DURHAM, N.C., Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the…
Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform
SINGAPORE – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001,…
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
Martinsried, Germany, and Marseille, France - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus,…
Aenova expands its advanced technology portfolio with cutting-edge hot melt extrusion platform
Starnberg, Germany, Aenova, a leading global contract development and manufacturing organization (CDMO), relies on various innovative technologies to improve the oral bioavailability of poorly soluble…
Ofichem acquires Avivia B.V. to expand formulation development capabilities
Nijmegen, Netherlands, Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a company specialized in formulation development based in Nijmegen, the Netherlands. The…
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
REYKJAVIK, Iceland and BURGDORF, Switzerland, Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
HERCULES, Calif. Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of…
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Salt Lake City, UT, Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s…
European Medicines Agency Grants Orphan Drug Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome (FXS)
LOS ANGELES, Calif., Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that…
Certara Announces Expansion of Clinical Technology Collaboration with Merck
RADNOR, Pa., Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of…
Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science
SAN DIEGO, Medvantx, a leading pharmacy services company, announced today that it acquired RxS, a leader in multichannel sample management and accountability solutions. The combined…
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
SOLANA BEACH, Calif., Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,…
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
TOKYO, Chugai Pharmaceutical Co., Ltd., and Gero PTE. LTD. , a Singapore-based biotechnology company, announced today that they have entered into a joint research and…
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics…
